PDS Biotech Q1 net loss $10.6M; VERSATILE-002 shows median OS of 30 months in HNSCC

PDS Biotechnology Corp

2024-Q1 EPS reported -$0.30

VERSATILE-002 Phase 2: median overall survival 30 months (vs 7-18 months for ICIs); BOR 34% (CPS≥1), 48% (CPS≥20).
Updated registrational trial strategy: triple combination Versamune HPV + PDS01ADC + pembrolizumab in first-line HNSCC.
Appointed Stephan Toutain as COO; brings commercial experience.
Two patents granted by Israel and Australia extending Versamune platform protection through 2036-2038.
Q1 net loss $10.6M ($0.30/share); cash $66.6M; R&D expenses $6.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PDS Biotechnology Corp reported the three months ended March 31, 2024 results: net income approximately $10.6 million, EPS $0.30 per basic share and diluted share.

Period: the three months ended March 31, 2024
Net income: approximately $10.6 million
EPS: $0.30 per basic share and diluted share
Result: reported results

Exact text from the filing

Reported net loss was approximately $10.6 million, or $0.30 per basic share and diluted share, for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-24-026107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.